Disclosed herein are methods relating to manufacturing an embolizing agent precursor. Manufacture of the embolizing agent precursor may involve mixing a first component contained within a first container with a second component contained within a second container, the first component including a plurality of negatively charged gaseous components and a first stabilizer, the second component comprising a plurality of positively charged oil components, a second stabilizer, and a cationic surfactant. Further steps may include mixing the first component with the second component such that the first and second component are held together as a single agglomerated entity.

Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof and lamivudine, processes for making such formulations, and the use of such formulations in the treatment of HIV infection, in particular in the treatment of HIV infection in pediatric patients.

The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof and lamivudine, processes for making such formulations, and the use of such formulations in the treatment of HIV infection, in particular in the treatment of HIV infection in pediatric patients.

The invention relates to a composition comprising at least one C4 component and at least one C3 component, wherein the C4 component consists of ornithine and/or arginine or a suitable derivative of ornithine and/or arginine, wherein the C3 component consists of methionine and/or S-adenosylmethionine or a suitable derivative of methionine and/or S-adenosylmethionine, and wherein the molar ratio between the C3 component and the C4 component is between 1:5 and 5:1. The invention further relates to a nutritional supplement.

The invention relates to a composition comprising at least one C4 component and at least one C3 component, wherein the C4 component consists of ornithine and/or arginine or a suitable derivative of ornithine and/or arginine, wherein the C3 component consists of methionine and/or S-adenosylmethionine or a suitable derivative of methionine and/or S-adenosylmethionine, and wherein the molar ratio between the C3 component and the C4 component is between 1:5 and 5:1. The invention further relates to a nutritional supplement.

In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.